Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. Am J Respir Crit Care Med164 (8 Pt 2): S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID11704611.
Urgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment”. British Journal of Dermatology173 (2): 404–415. doi:10.1111/bjd.13845. PMID25891046.
Bernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. Expert Opinion on Biological Therapy18 (4): 425–448. doi:10.1080/14712598.2018.1438406. PMID29431518.
Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. Journal of Allergy and Clinical Immunology137 (6): 1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID27040372.
“Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells”. Eur. J. Immunol.33 (4): 1030–40. (April 2003). doi:10.1002/eji.200323185. PMID12672069.
“Omalizumab and the risk of malignancy: results from a pooled analysis”. The Journal of Allergy and Clinical Immunology129 (4): 983–9.e6. (April 2012). doi:10.1016/j.jaci.2012.01.033. PMID22365654.
Chang TW (February 2000). “The pharmacological basis of anti-IgE therapy”. Nat. Biotechnol.18 (2): 157–62. doi:10.1038/72601. PMID10657120.
“Anti-IgE as a mast cell-stabilizing therapeutic agent”. The Journal of Allergy and Clinical Immunology117 (6): 1203–12. (June 2006). doi:10.1016/j.jaci.2006.04.005. PMID16750976.
“Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy”. Clin. Exp. Allergy35 (4): 408–16. (April 2005). doi:10.1111/j.1365-2222.2005.02191.x. PMID15836747.
“The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation”. The Journal of Allergy and Clinical Immunology115 (3): 459–65. (March 2005). doi:10.1016/j.jaci.2004.11.053. PMID15753888.
“Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE”. Ann Allergy Asthma Immunol104 (6): 537–9. (June 2010). doi:10.1016/j.anai.2010.04.011. PMID20568389.
“Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE”. Int. J. Urol.13 (5): 631–4. (May 2006). doi:10.1111/j.1442-2042.2006.01373.x. PMID16771742.
“Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab”. The Journal of Allergy and Clinical Immunology120 (4): 979–81. (October 2007). doi:10.1016/j.jaci.2007.07.041. PMID17931567.
de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (April 2013). “Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry”. J Asthma50 (3): 296–301. doi:10.3109/02770903.2012.757780. PMID23350994.
“Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria”. N Engl J Med368 (10): 924–35. (March 2013). doi:10.1056/NEJMoa1215372. PMID23432142.
“Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy”. The Journal of Allergy and Clinical Immunology132 (1): 101–9. (July 2013). doi:10.1016/j.jaci.2013.05.013. PMID23810097.
Pocket guide for asthma management and prevention. Global Initiatives for Asthma. 2013. “Archived copy”. 2013年5月21日時点のオリジナルよりアーカイブ。2013年7月7日閲覧。
nih.gov
pubmed.ncbi.nlm.nih.gov
Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. Am J Respir Crit Care Med164 (8 Pt 2): S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID11704611.
Urgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment”. British Journal of Dermatology173 (2): 404–415. doi:10.1111/bjd.13845. PMID25891046.
Bernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. Expert Opinion on Biological Therapy18 (4): 425–448. doi:10.1080/14712598.2018.1438406. PMID29431518.
Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. Journal of Allergy and Clinical Immunology137 (6): 1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID27040372.
“Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells”. Eur. J. Immunol.33 (4): 1030–40. (April 2003). doi:10.1002/eji.200323185. PMID12672069.
“Omalizumab and the risk of malignancy: results from a pooled analysis”. The Journal of Allergy and Clinical Immunology129 (4): 983–9.e6. (April 2012). doi:10.1016/j.jaci.2012.01.033. PMID22365654.
Chang TW (February 2000). “The pharmacological basis of anti-IgE therapy”. Nat. Biotechnol.18 (2): 157–62. doi:10.1038/72601. PMID10657120.
“Anti-IgE as a mast cell-stabilizing therapeutic agent”. The Journal of Allergy and Clinical Immunology117 (6): 1203–12. (June 2006). doi:10.1016/j.jaci.2006.04.005. PMID16750976.
“Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody”. Journal of Immunology158 (3): 1438–45. (February 1997). PMID9013989.
Scheinfeld N (2005). “Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody”. Dermatol. Online J.11 (1): 2. PMID15748543.
“Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy”. Clin. Exp. Allergy35 (4): 408–16. (April 2005). doi:10.1111/j.1365-2222.2005.02191.x. PMID15836747.
“The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation”. The Journal of Allergy and Clinical Immunology115 (3): 459–65. (March 2005). doi:10.1016/j.jaci.2004.11.053. PMID15753888.
“Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE”. Ann Allergy Asthma Immunol104 (6): 537–9. (June 2010). doi:10.1016/j.anai.2010.04.011. PMID20568389.
“Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE”. Int. J. Urol.13 (5): 631–4. (May 2006). doi:10.1111/j.1442-2042.2006.01373.x. PMID16771742.
“Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab”. The Journal of Allergy and Clinical Immunology120 (4): 979–81. (October 2007). doi:10.1016/j.jaci.2007.07.041. PMID17931567.
de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (April 2013). “Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry”. J Asthma50 (3): 296–301. doi:10.3109/02770903.2012.757780. PMID23350994.
“Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria”. N Engl J Med368 (10): 924–35. (March 2013). doi:10.1056/NEJMoa1215372. PMID23432142.
“Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy”. The Journal of Allergy and Clinical Immunology132 (1): 101–9. (July 2013). doi:10.1016/j.jaci.2013.05.013. PMID23810097.
